Source facts
FDA issued an approval letter for CANAGLIFLOZIN on 2026-07-24. The source metadata identifies ANDA 210451 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
CANAGLIFLOZIN — FDA Approval Letter (ANDA 210451)
Issued to TEVA PHARMS USA. Application is approved as submitted.
Issued
July 24, 2026Application
ANDA 505j • 210451
Product
CANAGLIFLOZIN
Company
TEVA PHARMS USA
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for CANAGLIFLOZIN?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: ANDA 210451.
- 3Submission: original application.
- 4Sponsor: TEVA PHARMS USA.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the CANAGLIFLOZIN approval letter
Is CANAGLIFLOZIN FDA approved?
This letter documents an FDA approval action: FDA approved ANDA 210451 for CANAGLIFLOZIN, sponsored by TEVA PHARMS USA, on July 24, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is ANDA 210451?
ANDA 210451 is the application under which FDA issued this approval letter for CANAGLIFLOZIN to TEVA PHARMS USA. The letter is dated July 24, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.